MedTrace Logo

Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)

NCT03033277 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2017-01-26

No results posted yet for this study

Summary

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). One of the most common treatments for POI is hormone replacement therapy (HRT), but HRT doesn't work well, and it has been shown to increase the risk of blood clots in the veins, ovarian cancer, and breast cancer. The ability of MSCs to differentiate into oocyte-like cells has been previously documented. Herein the purpose of this work is to evaluate the therapeutic potential of cell therapy in women suffering from POI.

Conditions

  • Primary Ovarian Insufficiency

Interventions

BIOLOGICAL

Placebo transplantation

Intraovarian injection of placebo through vagina under the guidance of ultrasonic.

BIOLOGICAL

HUC-MSCs transplantation

Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.

Sponsors & Collaborators

  • The Third Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Hongmei Wang, Doctor · State Key Laboratory of Stem Cell and Reproductive Biology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-04-30
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033277 on ClinicalTrials.gov